Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Slowdown of Buying Activities Not Seen in Market
February 18, 2002
- Kusuri Proverbs Reveal Japanese Spirit (3)
February 18, 2002
- Chugai Transfers Marketing Rights of Keiten to Fujisawa
February 18, 2002
- Drug Makers Should Conclude Labor Contracts with Hospitals for PMS: Pharmacy Expert
February 18, 2002
- Novartis Transfers Marketing Rights for Halospor to Toyama
February 18, 2002
- Use of Computers for Processing Medical Bills to Be Promoted
February 18, 2002
- Recovery of Business Performance Stressed by President: Tsumura
February 11, 2002
- Japanese Society of Process Chemistry Created
February 11, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
February 11, 2002
- Korosho Clarifies Marketing Approval System
February 11, 2002
- Good Results Obtained in Vascular Dementia PIII Study on Aricept: Int'l Congress
February 11, 2002
- Korosho Proposes to Reduce Re-pricing Ceiling from 25% to 15%
February 11, 2002
- Pravastatin Reduces Risk of Stroke: Prof. Sacks of Harvard
February 11, 2002
- Amrubicin, Gatifloxacin Recommended for Approval
February 11, 2002
- Efficient Drug Development Expected with Human Tissue Bank: JHSF
February 11, 2002
- Korosho Considers Issuing Its Own List of Essential Drugs
February 11, 2002
- WORLD NEWS IN BRIEF
February 11, 2002
- Number of Births Continues to Decrease
February 11, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 11, 2002
- Pharmacoeconomic Data Not Reflected in NHI Pricing: Expert
February 11, 2002
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…